

**OPTN/UNOS Histocompatibility Committee
Meeting Minutes
October 10, 2017
Conference Call**

**Robert Bray, PhD, D(ABHI), Chair
Cathi Murphey, PhD, HCLD/CC(ABB), Vice Chair**

Introduction

The Histocompatibility Committee (the Committee) met via Citrix GoToTraining teleconference on 10/10/2017 to discuss the following agenda items:

1. Review of Public Comment: *Review of HLA Tables (2016)*

The following is a summary of the Committee's discussions.

1. Review of Public Comment: *Review of HLA Tables (2016)*

The Committee had one proposal out for public comment from July 31, 2017, through October 2, 2017.

Summary of discussion:

The Committee reviewed the public comments that were submitted for the *Review of HLA Tables (2016)* proposal. In total, the proposal received nine comments on the OPTN website and one comment submitted by email from the American Society for Histocompatibility and Immunogenetics (ASHI) Accreditation Review Board. The Committee discussed each comment.

Several comments addressed the Committee's decision to use the G group for the HLA-DPB1 unacceptable antigen table. Commenters thought that the P group should be used in place of the G group; one comment explained that the P group has the same protein sequence which is relevant to the binding of HLA antibodies. The Committee considered using the P group and discussed the merits and drawbacks. One of the comments suggested having the table just list the P group and equivalences to simplify the table. A Committee member commented that it is important to list the allele level because of the ability for antibodies to bind to any polymorphism. The Committee agreed that reducing the entry of an allele to the broader group was not preferable for the table. Several Committee members commented that not listing at the allele level would also prevent the collection of frequencies for these alleles. The Committee agreed to discuss the P group vs. G group decision more at the in person meeting.

One Committee member asked about how the equivalency tables will change as labs move towards high resolution typing in the future; specifically for 0-ABDR matching, would points only be given only if there is an allele level match. The Committee Chair commented that it may come down to whether the data support better outcomes for allele level matching in that context. If so, then the Committee may consider that in the future. One Committee member asked if there is data about the number of labs that use high resolution typing vs. real time for deceased donor. The Committee will consider asking this on a future survey.

The Committee considered removing select broad antigens from the equivalency tables. They agreed to discuss this more at the in person meeting and review the frequencies of several broad antigens. The Committee also made several small additions to the equivalency tables based on several comments (for example, adding alleles to HLA-DR51).

The Committee decided after reviewing the comments on this call that there would need to be a comprehensive education effort that goes out with this proposal if it is approved by the Board.

Several comments suggest that there is a lack of understanding about how the equivalency tables in OPTN policy function and the community may benefit from some education.

Next steps:

The Committee will continue to discuss the remainder of the public comments at the in person meeting on October 24, 2017.

Upcoming Meeting

- October 24, 2017 – Richmond, VA

Attendance

- **Committee Members**
 - Bob Bray
 - Cathi Murphey
 - Adam Bingaman
 - Cathy Gebhart
 - Steve Geier
 - Chantale Lacelle
 - Peter Lalli
 - Mayra Lopez-Cepero
 - Gabriel Maine
 - Rajalingam Raja
 - Carley Shaut
 - Craig Van De Walker
- **HRSA Representatives**
 - Raelene Skerda
- **SRTR Staff**
 - Katie Audette
- **OPTN/UNOS Staff**
 - Alison Wilhelm
 - Betsy Gans
 - Anna Kucheryavaya
 - Kimberly Taylor